Why BillionToOne ($BLLN) will moonshot

**$BLLN BillionToOne is the most interesting stock I've looked at in a while and I think most people are sleeping on it. Here's everything I found after going super deep.** I spent a lot of time researching this one so buckle up. This is a long one but I genuinely think it's worth it. **What they actually do** Most people describe BLLN as a prenatal testing company which is the wrong frame entirely. BillionToOne built a molecular counting platform called QCT (Quantitative Counting Templates) that can detect and count individual DNA molecules in blood at single-molecule resolution. That's roughly 1000x more sensitive than standard next-gen sequencing approaches. The prenatal test was just the first use case because that market had the clearest path to reimbursement. The underlying technology can quantify any DNA signal in blood which means the roadmap extends way beyond prenatal into oncology, rare disease, pharmacogenomics, MRD monitoring, and potentially infectious disease. Their prenatal product UNITY Complete does something no competitor does in a single blood draw. It screens for chromosomal aneuploidies, single-gene recessive disorders like cystic fibrosis and sickle cell disease, and fetal antigen status all at once. Natera, Illumina, and everyone else requires separate tests to get equivalent coverage. BillionToOne just hit 1 million cumulative UNITY tests delivered and has captured roughly 15% of the US prenatal market. The oncology platform called Northstar is where I think the real upside lives long term. They just got Medicare coverage for Northstar Select which is a liquid biopsy test for advanced solid tumors. In a head to head study it detected 51% more clinically actionable mutations than competing tests. Oncology revenue grew 748% in 2025 from $2.9M to $25M. Still tiny but attacking a $50B+ addressable market. **The financials are genuinely insane for a diagnostics company** Revenue went $72M in 2023 to $153M in 2024 to $305M in 2025. That's 100% growth two years in a row. They turned GAAP profitable in 2025. Positive free cash flow. 70%+ gross margins. These three things together while growing over 40% annually is almost unheard of in this space. Baron Capital called it out specifically because it's so rare. 2026 guidance is $430 to $445M which represents about 43% growth from 2025. They've already raised guidance twice this year. **The CEO is the most important part of this story** Oguzhan Atay is a Princeton summa cum laude in molecular biology with minors in CS, physics, and applied math. Then a Stanford PhD in systems biology where he actually invented the QCT technology himself. He's not a business guy who licensed someone else's science. He built the core platform from the ground up and he knows where it can go next in ways that competitors genuinely cannot reverse engineer quickly. The most important signal I found was from Neotribe Ventures, an early backer, who said BillionToOne never missed a single quarterly target across their entire private company lifecycle. Not once. For a high-growth biotech that's an almost unbelievable statement. He also turned down acquisition offers to build this independently. That's the right call given what they're building. **Why I think most people are mispricing the long-term** Natera built a roughly $11B company almost entirely off prenatal and MRD testing using technology that is genuinely inferior to QCT. BillionToOne is attacking prenatal AND oncology AND pharmacogenomics AND potentially MRD with a better underlying platform and a founder who invented the technology. If they execute the platform vision over 10 years the revenue potential is $3B to $5B+. Even at a conservative 8x revenue multiple that's a $25 to $40B company from a $3.6B market cap today. **Price targets honestly** End of 2026 I think $95 to $115 is reasonable. The guidance midpoint is $437M in revenue and at peer multiples that puts market cap at $4.5B to $5.5B. 5 year base case is around $250 to $320 per share assuming revenue compounds at 30% annually to around $1.6B and the multiple compresses a bit as they mature. Bull case if oncology really scales and Unity Confirm (their new no-amniocentesis test that showed 100% concordance in early data) becomes standard of care is $400 to $600. That's a 5 to 7x from here. **The real risks** The US healthcare reimbursement system is the thing that keeps me up at night with this one. You can have the best technology in the world and get destroyed if CMS decides not to cover your tests. A lot of the single-gene NIPT coverage is still not universal. If they get an adverse coverage determination the stock craters fast regardless of how good the science is. The second risk is Illumina since they own the sequencing infrastructure the whole industry runs on and could theoretically try to commoditize what BillionToOne built. Short interest is also elevated at around 9.84% with a borrow rate near 90% so there's a lot of pressure baked in. Lock-up expiration is coming up in May/June 2026 which could create a cleaner entry point if there's selling pressure from pre-IPO investors. **Bottom line** Earnings are today after close (May 6, 4:30 PM ET). Q4 2025 was a massive beat, the reimbursement momentum is real, and management has a perfect track record of execution. I'm not going all in before a binary event but I think the 5-year thesis here is one of the more compelling setups in public biotech/diagnostics right now. This isn't a meme stock. This is a founder-scientist with a genuine technology moat attacking multiple massive markets who has never missed a target. That combination is rare. Not financial advice obviously. Do your own research. **Positions: 1420 shares, 6 x 12/18/2026 $125 calls** [robinhood acc](https://preview.redd.it/dlzqacqg3kzg1.png?width=1516&format=png&auto=webp&s=3300265ad8c4165381b178f88e00b73db97a203a) [webull acc](https://preview.redd.it/cu0g7vnh3kzg1.png?width=1320&format=png&auto=webp&s=16ad8b67046896db2389634759fab7e529814c7b)